SBIR Phase I: Star Polymer Micelles as Targeted Drug Delivery System

这个小型企业创新研究(SBIR)第一阶段项目将开发一种用于靶向递送化疗药物的新型纳米结构聚合物胶束系统。将合成一种星形结构聚合物作为药物输送载体。星形聚合物在水条件下会形成单分子胶束。疏水性药物可以被包裹在单分子胶束中，并通过主动靶向过程传递到肿瘤组织。胶束表面的官能团将作为靶向部分，并将药物载体引导到所需的癌细胞。该计划的具体目标是合成和表征候选的STAR聚合物，并进行体外内皮细胞黏附实验，以确定该STAR聚合物与v3和v5整合素的亲和力。在商业上，有了这种拟议的新药物输送系统，通过主动靶向更具选择性的输送是可能的。这将减少药物剂量和不良副作用，并使癌症化疗更有效。新的药物输送系统几乎对医学的每个分支都产生了影响。仅先进药物输送系统在美国的年销售额就超过100亿美元，而且还在迅速增长。

This Small Business Innovation Research (SBIR) Phase I project will develop a novel nanostructured polymer micelle system for targeted delivery of chemotherapeutic drugs. A star structural polymer will be synthesized for use as the drug delivery vehicle. The star polymer will form unimolecular micelles under aqueous conditions. Hydrophobic drugs can be encapsulated in the unimolecular micelles and delivered to the cancer tissue via an active targeting process. Functional groups at the micelles surface will act as targeting moieties and lead the drug carrier to the desired cancer cells. The specific aims in the proposed program are to synthesize and characterize a candidate star polymer, and to conduct in vitro endothelial cell adhesive assay to determine the affinity of the star polymer to v3 and v5 integrins. Commercially, with this proposed new drug delivery system, more selective delivery by active targeting is possible. This will reduce the drug dose and undesirable side effects and make chemotherapy for cancer treatment more efficient. New drug delivery systems have had an impact on nearly every branch of medicine. Annual sales in the United States of advanced drug delivery systems exceed $10 billion alone and are rising rapidly.